Cerebrospinal fluid abacavir concentrations in HIV-positive patients following once-daily administration.
Andrea CalcagnoC PinnettiA De NicolòE ScarvaglieriM GisslenM TempestilliAntonio D'AvolioV FedeleG Di PerriA AntinoriS BonoraPublished in: British journal of clinical pharmacology (2018)
Abacavir is a widely used nucleotide reverse transcriptase inhibitor, for which cerebrospinal fluid (CSF) exposure has been previously assessed in twice-daily recipients. We studied abacavir CSF concentrations in 61 and nine HIV-positive patients taking abacavir once daily and twice daily, respectively. Patients on once-daily abacavir had higher plasma and CSF concentrations (96 vs. 22 ng ml-1 , P = 0.038 and 123 vs. 49 ng ml-1 , P = 0.038) but similar CSF-to-plasma ratios (0.8 vs. 0.5, P = 0.500). CSF abacavir concentrations were adequate in patients receiving once-daily treatment.